3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other solid neoplasm
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Conditions
Wilms Tumor
1
Stomach Neoplasms
1
Sarcoma, Ewing
1
Sarcoma, Clear Cell
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Retinoblastoma
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hepatoblastoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Advanced Pancreatic Cancer
1
Interventions
pembrolizumab
47
Nivolumab
34
Sunitinib
18
Cyclophosphamide
18
Everolimus
17
Ipilimumab
15
cabozantinib
14
pazopanib
13
Bevacizumab
13
fludarabine
12
atezolizumab
11
temsirolimus
10
Magnetic Resonance Spectroscopy
10
Sorafenib
9
aldesleukin
8
Specimen Handling
8
Paclitaxel
8
Sirolimus
7
CTLA-4 Antigen
7
Axitinib
7
belzutifan
6
Radiosurgery
6
Oxaliplatin
6
Interleukin-2
6
Fluorouracil
6
spartalizumab
5
avelumab
5
Leucovorin
5
Irinotecan
5
Docetaxel
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Carcinoma, Renal Cell
×
Simvastatin
×
Clear all
NCT02390843
2020-04-03
AflacST1402
Emory University
Phase 1
Completed
13 enrolled